Pfizer is Now Testing a COVID-19 Pill
The treatment is a potent protease inhibitor
Pharmaceutical giant Pfizer has kicked off early stage clinical trials of an experimental oral antiviral drug to treat COVID-19.
The company announced on Tuesday the phase one trial of the drug, PF-07321332, is currently taking place in the U.S.
The treatment is a potent protease inhibitor, the same kind of technology used to treat HIV and hepatitis C. Protease inhibitors bind to a viral enzyme and prevent the virus from replicating in the cell.
Please select this link to read the complete article from The Hill.